Cargando…
Health-Related Quality of Life and Health Resource Utilization in Patients with Primary Immunodeficiency Disease Prior to and Following 12 Months of Immunoglobulin G Treatment
PURPOSE: Health-related quality of life (HRQOL) has not been examined in patients with predominant antibody deficiency both pre- and post-immunoglobulin G (IgG) treatment initiation. HRQOL and health resource utilization (HRU) were assessed in newly diagnosed patients with primary immunodeficiency d...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896988/ https://www.ncbi.nlm.nih.gov/pubmed/27091140 http://dx.doi.org/10.1007/s10875-016-0279-0 |
_version_ | 1782436061693083648 |
---|---|
author | Routes, John Costa-Carvalho, Beatriz Tavares Grimbacher, Bodo Paris, Kenneth Ochs, Hans D. Filipovich, Alexandra Hintermeyer, Mary de Melo, Karina Mescouto Workman, Sarita Ito, Diane Ye, Xiaolan Bonnet, Patrick Li-McLeod, Josephine |
author_facet | Routes, John Costa-Carvalho, Beatriz Tavares Grimbacher, Bodo Paris, Kenneth Ochs, Hans D. Filipovich, Alexandra Hintermeyer, Mary de Melo, Karina Mescouto Workman, Sarita Ito, Diane Ye, Xiaolan Bonnet, Patrick Li-McLeod, Josephine |
author_sort | Routes, John |
collection | PubMed |
description | PURPOSE: Health-related quality of life (HRQOL) has not been examined in patients with predominant antibody deficiency both pre- and post-immunoglobulin G (IgG) treatment initiation. HRQOL and health resource utilization (HRU) were assessed in newly diagnosed patients with primary immunodeficiency disease (PIDD) pre- and 12 months post-IgG treatment initiation. METHODS: Adults (age ≥18 years) completed the 36-item Short Form Health Survey, version 2; pediatric patients (PP)/caregivers completed the Pediatric Quality of Life Inventory (PedsQL). Scores were compared with normative data from the US general population (GP) and patients with other chronic conditions (OCC). RESULTS: Seventeen adult patients (APs), 8 PPs, and 8 caregivers completed baseline assessments. APs had significantly lower baseline mean physical component summary scores versus GP (37.4 vs 50.5, p < 0.01) adults with chronic back pain (44.1, p < 0.05) or cancer (44.4, p < 0.05) and lower mental component summary scores versus GP (41.6 vs 49.2, p < 0.05). PPs had lower PedsQL total (63.1 vs 82.7), physical summary (64.5 vs 84.5), and psychosocial summary (62.5 vs 81.7) scores versus GP. Post-IgG treatment, 14 APs, 6 PPs, and 8 caregivers completed assessments. Hospital admissions (0.2 versus 1.8, p < 0.01), serious infections (3.3 versus 10.9, p < 0.01) and antibiotic prescriptions (3.0 versus 7.1; p < 0.01) decreased significantly overall. While APs reported significant improvement in role-physical (p = 0.01), general health (p < 0.01), and social functioning (p = 0.02) and caregivers in vitality (p < 0.01), PPs did not. CONCLUSIONS: Pre-IgG treatment, patients with PIDD experienced diminished HRQOL versus GP and patients with OCC; post-treatment, HRU decreased and certain HRQOL aspects improved for APs and caregivers. |
format | Online Article Text |
id | pubmed-4896988 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-48969882016-06-27 Health-Related Quality of Life and Health Resource Utilization in Patients with Primary Immunodeficiency Disease Prior to and Following 12 Months of Immunoglobulin G Treatment Routes, John Costa-Carvalho, Beatriz Tavares Grimbacher, Bodo Paris, Kenneth Ochs, Hans D. Filipovich, Alexandra Hintermeyer, Mary de Melo, Karina Mescouto Workman, Sarita Ito, Diane Ye, Xiaolan Bonnet, Patrick Li-McLeod, Josephine J Clin Immunol Original Article PURPOSE: Health-related quality of life (HRQOL) has not been examined in patients with predominant antibody deficiency both pre- and post-immunoglobulin G (IgG) treatment initiation. HRQOL and health resource utilization (HRU) were assessed in newly diagnosed patients with primary immunodeficiency disease (PIDD) pre- and 12 months post-IgG treatment initiation. METHODS: Adults (age ≥18 years) completed the 36-item Short Form Health Survey, version 2; pediatric patients (PP)/caregivers completed the Pediatric Quality of Life Inventory (PedsQL). Scores were compared with normative data from the US general population (GP) and patients with other chronic conditions (OCC). RESULTS: Seventeen adult patients (APs), 8 PPs, and 8 caregivers completed baseline assessments. APs had significantly lower baseline mean physical component summary scores versus GP (37.4 vs 50.5, p < 0.01) adults with chronic back pain (44.1, p < 0.05) or cancer (44.4, p < 0.05) and lower mental component summary scores versus GP (41.6 vs 49.2, p < 0.05). PPs had lower PedsQL total (63.1 vs 82.7), physical summary (64.5 vs 84.5), and psychosocial summary (62.5 vs 81.7) scores versus GP. Post-IgG treatment, 14 APs, 6 PPs, and 8 caregivers completed assessments. Hospital admissions (0.2 versus 1.8, p < 0.01), serious infections (3.3 versus 10.9, p < 0.01) and antibiotic prescriptions (3.0 versus 7.1; p < 0.01) decreased significantly overall. While APs reported significant improvement in role-physical (p = 0.01), general health (p < 0.01), and social functioning (p = 0.02) and caregivers in vitality (p < 0.01), PPs did not. CONCLUSIONS: Pre-IgG treatment, patients with PIDD experienced diminished HRQOL versus GP and patients with OCC; post-treatment, HRU decreased and certain HRQOL aspects improved for APs and caregivers. Springer US 2016-04-18 2016 /pmc/articles/PMC4896988/ /pubmed/27091140 http://dx.doi.org/10.1007/s10875-016-0279-0 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Routes, John Costa-Carvalho, Beatriz Tavares Grimbacher, Bodo Paris, Kenneth Ochs, Hans D. Filipovich, Alexandra Hintermeyer, Mary de Melo, Karina Mescouto Workman, Sarita Ito, Diane Ye, Xiaolan Bonnet, Patrick Li-McLeod, Josephine Health-Related Quality of Life and Health Resource Utilization in Patients with Primary Immunodeficiency Disease Prior to and Following 12 Months of Immunoglobulin G Treatment |
title | Health-Related Quality of Life and Health Resource Utilization in Patients with Primary Immunodeficiency Disease Prior to and Following 12 Months of Immunoglobulin G Treatment |
title_full | Health-Related Quality of Life and Health Resource Utilization in Patients with Primary Immunodeficiency Disease Prior to and Following 12 Months of Immunoglobulin G Treatment |
title_fullStr | Health-Related Quality of Life and Health Resource Utilization in Patients with Primary Immunodeficiency Disease Prior to and Following 12 Months of Immunoglobulin G Treatment |
title_full_unstemmed | Health-Related Quality of Life and Health Resource Utilization in Patients with Primary Immunodeficiency Disease Prior to and Following 12 Months of Immunoglobulin G Treatment |
title_short | Health-Related Quality of Life and Health Resource Utilization in Patients with Primary Immunodeficiency Disease Prior to and Following 12 Months of Immunoglobulin G Treatment |
title_sort | health-related quality of life and health resource utilization in patients with primary immunodeficiency disease prior to and following 12 months of immunoglobulin g treatment |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896988/ https://www.ncbi.nlm.nih.gov/pubmed/27091140 http://dx.doi.org/10.1007/s10875-016-0279-0 |
work_keys_str_mv | AT routesjohn healthrelatedqualityoflifeandhealthresourceutilizationinpatientswithprimaryimmunodeficiencydiseasepriortoandfollowing12monthsofimmunoglobulingtreatment AT costacarvalhobeatriztavares healthrelatedqualityoflifeandhealthresourceutilizationinpatientswithprimaryimmunodeficiencydiseasepriortoandfollowing12monthsofimmunoglobulingtreatment AT grimbacherbodo healthrelatedqualityoflifeandhealthresourceutilizationinpatientswithprimaryimmunodeficiencydiseasepriortoandfollowing12monthsofimmunoglobulingtreatment AT pariskenneth healthrelatedqualityoflifeandhealthresourceutilizationinpatientswithprimaryimmunodeficiencydiseasepriortoandfollowing12monthsofimmunoglobulingtreatment AT ochshansd healthrelatedqualityoflifeandhealthresourceutilizationinpatientswithprimaryimmunodeficiencydiseasepriortoandfollowing12monthsofimmunoglobulingtreatment AT filipovichalexandra healthrelatedqualityoflifeandhealthresourceutilizationinpatientswithprimaryimmunodeficiencydiseasepriortoandfollowing12monthsofimmunoglobulingtreatment AT hintermeyermary healthrelatedqualityoflifeandhealthresourceutilizationinpatientswithprimaryimmunodeficiencydiseasepriortoandfollowing12monthsofimmunoglobulingtreatment AT demelokarinamescouto healthrelatedqualityoflifeandhealthresourceutilizationinpatientswithprimaryimmunodeficiencydiseasepriortoandfollowing12monthsofimmunoglobulingtreatment AT workmansarita healthrelatedqualityoflifeandhealthresourceutilizationinpatientswithprimaryimmunodeficiencydiseasepriortoandfollowing12monthsofimmunoglobulingtreatment AT itodiane healthrelatedqualityoflifeandhealthresourceutilizationinpatientswithprimaryimmunodeficiencydiseasepriortoandfollowing12monthsofimmunoglobulingtreatment AT yexiaolan healthrelatedqualityoflifeandhealthresourceutilizationinpatientswithprimaryimmunodeficiencydiseasepriortoandfollowing12monthsofimmunoglobulingtreatment AT bonnetpatrick healthrelatedqualityoflifeandhealthresourceutilizationinpatientswithprimaryimmunodeficiencydiseasepriortoandfollowing12monthsofimmunoglobulingtreatment AT limcleodjosephine healthrelatedqualityoflifeandhealthresourceutilizationinpatientswithprimaryimmunodeficiencydiseasepriortoandfollowing12monthsofimmunoglobulingtreatment |